CareDx Inc ( (CDNA) ) has released its Q1 earnings. Here is a breakdown of the information CareDx Inc presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
CareDx, Inc., headquartered in Brisbane, California, is a precision medicine company specializing in genomics-based solutions for transplant patients, offering testing services, products, and digital healthcare solutions.
In the first quarter of 2025, CareDx reported a revenue increase of 18% year-over-year, reaching $84.7 million. The company also achieved its seventh consecutive quarter of growth in testing services volume, highlighting its expanding footprint in the transplant care sector.
Key financial metrics for the quarter include a 15% increase in testing services revenue to $61.9 million and a GAAP net loss of $10.4 million, which improved significantly from the previous year’s $19.9 million loss. The company also reported a non-GAAP net income of $5.4 million and a positive adjusted EBITDA of $4.6 million. CareDx’s cash position remains strong with $231 million in cash, cash equivalents, and marketable securities.
Strategically, CareDx launched expanded indications for its AlloSure testing services and advanced its AlloHeme trial, while also restructuring its Revenue Cycle Management team to drive growth. The company reaffirmed its full-year 2025 guidance, projecting revenue between $365 million and $375 million and an adjusted EBITDA of $29 million to $33 million.
Looking ahead, CareDx remains focused on expanding its market presence and enhancing its service offerings, with management optimistic about continued growth and innovation in the transplant care sector.